Treating Acute Pancreatitis With Dabigatran, a Pilot Study

    Not Recruiting
  • participants needed
  • sponsor
    Mayo Clinic
Updated on 7 October 2022
acute pancreatitis


Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute pancreatitis.


Subjects with acute pancreatitis who meet the inclusion and exclusion criteria for the study will be recruited. Subjects will be randomized to receive either Dabigatran 150mg daily for three days or standard treatment. Vital signs, CBC, inflammatory markers and BMP, and bleeding complications will be evaluated daily for the next 7 days of until discharge whichever is sooner.

Condition Acute Pancreatitis
Treatment Standard of Care, Dabigatran Etexilate Mesylate
Clinical Study IdentifierNCT03807856
SponsorMayo Clinic
Last Modified on7 October 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note